Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial

被引：44

作者：

Garlipp, B. ^{[1
]}

Gibbs, P. ^{[10
]}

Van Hazel, G. A. ^{[11
]}

Jeyarajah, R. ^{[12
]}

Martin, R. C. G. ^{[13
]}

Bruns, C. J. ^{[4
]}

Lang, H. ^{[3
]}

Manas, D. M. ^{[14
]}

Ettorre, G. M. ^{[16
]}

Pardo, F. ^{[17
,18
]}

Donckier, V. ^{[20
]}

Benckert, C. ^{[5
]}

van Gulik, T. M. ^{[21
]}

Goere, D. ^{[22
]}

Schoen, M. ^{[7
]}

Pratschke, J. ^{[6
]}

Bechstein, W. O. ^{[8
]}

de la Cuesta, A. M. ^{[19
]}

Adeyemi, S. ^{[15
]}

Ricke, J. ^{[2
,9
]}

Seidensticker, M. ^{[1
,2
,9
]}

机构：

[1] Otto von Guericke Univ Hosp, Leipziger Str 44, D-39120 Magdeburg, Germany

[2] Deutsch Akad Mikrotherapie, Magdeburg, Germany

[3] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Gen Visceral & Transplant Surg, Mainz, Germany

[4] Univ Hosp Cologne, Cologne, Germany

[5] Vivantes Klinikum Friedrichshain, Berlin, Germany

[6] Charite Univ Med Berlin, Berlin, Germany

[7] Stadt Klinikum Karlsruhe, Karlsruhe, Germany

[8] Univ Hosp Frankfurt, Dept Gen & Visceral Surg, Frankfurt, Germany

[9] Klinikum Univ Munchen, Klin & Poliklin Radiol, Munich, Germany

[10] Western Hlth, Dept Med Oncol, Melbourne, Vic, Australia

[11] Sir Charles Gairdner Hosp, Perth, WA, Australia

[12] Methodist Richardson Med Ctr, Dallas, TX USA

[13] Univ Louisville, Div Surg Oncol, Louisville, KY 40292 USA

[14] Freeman Rd Hosp, Dept Hepatopancreatobiliary Surg, Newcastle Upon Tyne, Tyne & Wear, England

[15] Statsxperts Consulting Ltd, Hemel Hempstead, England

[16] Osped San Camillo Forlanini, Rome, Italy

[17] Clin Univ Navarra, Hepatopancreaticobiliary Surg & Oncol, Pamplona, Spain

[18] Inst Invest Sanitaria Navarra, Pamplona, Spain

[19] Radcon Hispania, Pamplona, Spain

[20] Jules Bordet Inst, Brussels, Belgium

[21] Acad Med Ctr, Amsterdam, Netherlands

[22] Inst Gustave Roussy, Villejuif, France

来源：

BRITISH JOURNAL OF SURGERY | 2019年 / 106卷 / 13期

关键词：

RADIATION-THERAPY; HEPATIC RESECTION; CETUXIMAB; SURGERY; TERM; RADIOEMBOLIZATION; BEVACIZUMAB; SURVIVAL; ABLATION; DISEASE;

D O I：

10.1002/bjs.11283

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Background Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX-based chemotherapy. Methods Baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic disease status, and information on clinical and scanning time points. Technical resectability was defined as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient's liver metastases as surgically removable. Results Some 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline difference in the proportion of technically resectable liver metastases between SIRT (29, 11 center dot 9 per cent) and control (25, 11 center dot 0 per cent) arms (P = 0 center dot 775). At follow-up, significantly more patients in both arms were deemed technically resectable compared with baseline: 159 of 472 (33 center dot 7 per cent) versus 54 of 472 (11 center dot 4 per cent) respectively (P = 0 center dot 001). More patients were resectable in the SIRT than in the control arm: 93 of 244 (38 center dot 1 per cent) versus 66 of 228 (28 center dot 9 per cent) respectively (P < 0 center dot 001). Conclusion Adding SIRT to chemotherapy may improve the resectability of unresectable CRLM.

引用

页码：1837 / 1846

页数：10

共 32 条

[11] Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial [J].

Folprecht, Gunnar ;

Gruenberger, Thomas ;

Bechstein, Wolf O. ;

Raab, Hans-Rudolf ;

Lordick, Florian ;

Hartmann, Joerg T. ;

Lang, Hauke ;

Frilling, Andrea ;

Stoehlmacher, Jan ;

Weitz, Juergen ;

Konopke, Ralf ;

Stroszczynski, Christian ;

Liersch, Torsten ;

Ockert, Detlev ;

Herrmann, Thomas ;

Goekkurt, Eray ;

Parisi, Fabio ;

Koehne, Claus-Henning .

LANCET ONCOLOGY, 2010, 11 (01) :38-47

[12] Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study [J].

Gibbs, Peter ;

Gebski, Val ;

Van Buskirk, Mark ;

Thurston, Kenneth ;

Cade, David N. ;

Van Hazel, Guy A. .

BMC CANCER, 2014, 14

[13] Cause of Death from Liver Metastases in Colorectal Cancer [J].

Helling, Thomas S. ;

Martin, Magdeline .

ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) :501-506

[14] Liver Resection for Metastatic Disease After Y90 Radioembolization: A Case Series with Long-Term Follow-Up [J].

Henry, Leonard R. ;

Hostetter, Richard B. ;

Ressler, Brittany ;

Bowser, Ingrid ;

Yan, Min ;

Vaghefi, Houman ;

Abad, John ;

Gulec, Seza ;

Schwarz, Roderich E. .

ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (02) :467-474

[15] Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases [J].

Homayounfar, K. ;

Bleckmann, A. ;

Helms, H. -J. ;

Lordick, F. ;

Rueschoff, J. ;

Conradi, L. -C. ;

Sprenger, T. ;

Ghadimi, M. ;

Liersch, T. .

BRITISH JOURNAL OF SURGERY, 2014, 101 (05) :550-557

[16] Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer [J].

Jones, Robert P. ;

Hamann, Susanne ;

Malik, Hassan Z. ;

Fenwick, Stephen W. ;

Poston, Graeme J. ;

Folprecht, Gunnar .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) :1590-1601

[17] Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer [J].

Loupakis, Fotios ;

Cremolini, Chiara ;

Masi, Gianluca ;

Lonardi, Sara ;

Zagonel, Vittorina ;

Salvatore, Lisa ;

Cortesi, Enrico ;

Tomasello, Gianluca ;

Ronzoni, Monica ;

Spadi, Rosella ;

Zaniboni, Alberto ;

Tonini, Giuseppe ;

Buonadonna, Angela ;

Amoroso, Domenico ;

Chiara, Silvana ;

Carlomagno, Chiara ;

Boni, Corrado ;

Allegrini, Giacomo ;

Boni, Luca ;

Falcone, Alfredo .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17) :1609-1618

[18] Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study [J].

Malik, H. ;

Khan, A. Z. ;

Berry, D. P. ;

Cameron, I. C. ;

Pope, I. ;

Sherlock, D. ;

Helmy, S. ;

Byrne, B. ;

Thompson, M. ;

Pulfer, A. ;

Davidson, B. .

EJSO, 2015, 41 (04) :499-505

[19] Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3 [J].

Modest, D. P. ;

Denecke, T. ;

Pratschke, J. ;

Ricard, I. ;

Lang, H. ;

Bemelmans, M. ;

Becker, T. ;

Rentsch, M. ;

Seehofer, D. ;

Bruns, C. J. ;

Gebauer, B. ;

Modest, H. I. ;

Held, S. ;

Folprecht, G. ;

Heinemann, V. ;

Neumann, U. P. .

EUROPEAN JOURNAL OF CANCER, 2018, 88 :77-86

[20] Short- and-long term results of intraoperative radiofrequency ablation of liver metastases [J].

Navarra, G ;

Ayav, A ;

Weber, JC ;

Jensen, SL ;

Smadga, C ;

Nicholls, JP ;

Habib, NA ;

Jiao, LR .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2005, 20 (06) :521-528

← 1 2 3 4 →